Correction to: Once‑Monthly Long‑Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co‑occurring Substance Use Disorders: A Multicentre, Observational Study
A randomized, 1-year follow-up study comparing LAI aripiprazole with LAI paliperidone in patients with psychosis, mostly schizophrenia, and SUD reported a large effect of the change from baseline in the CGI severity score, from 5.9 to 2.4 for LAI aripiprazole and from 5.7 to 2.6 for LAI risperidone...
Main Authors: | Nestor Szerman, Ignacio Basurte-Villamor, Pablo Vega, Jose Martinez-Raga, Carlos Parro-Torres, Julia Cambra Almerge, Lara Grau-López, Mario De Matteis, Francisco Arias |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2020-02-01
|
Series: | Drugs - Real World Outcomes |
Online Access: | https://doi.org/10.1007/s40801-020-00184-w |
Similar Items
-
Once-Monthly Long-Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co-occurring Substance Use Disorders: A Multicentre, Observational Study
by: Nestor Szerman, et al.
Published: (2020-02-01) -
Schizophrenia relapse and the clinical usefulness of once-monthly aripiprazole depot injection
by: Wang SM, et al.
Published: (2014-08-01) -
Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
by: Daniel Schöttle, et al.
Published: (2018-11-01) -
Correction to: Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
by: Daniel Schöttle, et al.
Published: (2018-12-01) -
The effect of switching from oral low-dose aripiprazole to aripiprazole once-monthly 300 mg on the quality of life in three patients with schizophrenia
by: Hidenobu Suzuki, et al.
Published: (2017-05-01)